



National HealthCare Corp. (NHC)

Updated March 2nd, 2024, by Ian Bezek

Key Metrics

Current Price:	\$96	5 Year CAGR Estimate:	4.1%	Market Cap:	\$1.4 B
Fair Value Price:	\$71	5 Year Growth Estimate:	8.0%	Ex-Dividend Date:	03/27/24
% Fair Value:	135%	5 Year Valuation Multiple Estimate:	-5.8%	Dividend Payment Date:	05/01/24
Dividend Yield:	2.5%	5 Year Price Target	\$104	Years Of Dividend Growth:	2
Dividend Risk Score:	F	Retirement Suitability Score:	F	Rating:	Hold

Overview & Current Events

National HealthCare was founded in 1971 to own and manage medical facilities. It operates skilled nursing facilities, home and hospice agencies, assisted living facilities, independent living facilities, and behavioral health hospitals. Besides operating its own facilities, National HealthCare leases some facilities to third-party operators. As of December 31st, 2023, National HealthCare operated or managed 68 skilled nursing facilities with 8,732 licensed beds in addition to its assortment of other healthcare, homecare, and hospice assets.

National HealthCare was traditionally a stable business with predictable growth. The pandemic upended this, however. Earnings plunged in 2020, soared in 2021 thanks to government relief payments, and then plunged again in 2022 as the payments wound down. Now, however, things are returning to normal with 2023 being a more standard year for the company. However, National HealthCare has adjusted its portfolio a bit to reflect the changing healthcare marketplace; the company left the Massachusetts and New Hampshire markets in the third quarter of 2022 as it moved on from seven facilities in those states. This concentrates National HealthCare's focus on its home market in the Southeast.

National HealthCare reported its fourth quarter results on February 16th, 2024. Adjusted earnings-per-share of \$1.03 rose from the \$0.72 figure recorded in the same period of 2022. Revenues surged 14% to \$301 million for the quarter. The firm's operating results improved markedly as pandemic-related headwinds have finally subsided. These Q4 results were much better than expected, and we've increased our earnings outlook accordingly. Finally, we would note that in the company's GAAP earnings, they reported a \$12 million profit this quarter due to the increase in the value of their marketable equity securities portfolio. We exclude these non-core earnings from our earnings estimates going forward.

Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
EPS	\$3.14	\$3.20	\$3.32	\$3.69	\$3.87	\$4.44	\$2.72	\$5.32	\$2.42	\$3.55	\$3.74	\$5.50
DPS	\$1.34	\$1.48	\$1.75	\$1.89	\$1.98	\$2.06	\$2.08	\$2.08	\$2.26	\$2.34	\$2.36	\$2.74
Shares¹	14	15	16	15	15	15	15	15	15	15	15	15

National HealthCare had a generally increasing earnings-per-share trend over the past decade; at least that was the case until March 2020. With the onset of the pandemic, however, the business faced many additional costs for keeping facilities safe and well-staffed with qualified healthcare professionals. National HealthCare received \$47.5 million and \$63.4 million of CARES Act government relief in 2020 and 2021 respectively, which added a great deal to the company's overall earnings.

As this emergency aid has wound down, however, the company's earnings slumped in 2022. 2023 was a much better year though, and we anticipate the firm hitting an 8% annualized earnings growth rate going forward.

The company had delivered a strong series of dividend hikes prior to 2020. However, the dividend was paused during the pandemic before hikes resumed in 2022. The much better earnings performance in 2023 opens the door to larger dividend hikes over the next few years.

¹ In millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



National HealthCare Corp. (NHC)

Updated March 2nd, 2024, by Ian Bezek

Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	17.8	19.9	19.6	18.6	18.0	18.2	25.3	13.4	26.8	21.4	25.7	19.0
Avg. Yld.	2.4%	2.3%	2.7%	2.8%	2.8%	2.6%	3.0%	2.0%	3.7%	3.1%	2.5%	2.6%

National HealthCare has generally maintained a P/E ratio in the mid-to-high teens. Currently, the company's P/E ratio is above average due to a sharp rally in the stock price over the past two quarters. We expect the firm's P/E ratio to settle back at 19 in future years as this is not normally a firm that commands a premium valuation.

The company has traditionally offered a dividend yield between 2.5% and 3.0%. The payout ratio has fallen back to the lower end of that range today.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	43%	46%	53%	51%	51%	46%	76%	39%	93%	66%	63%	50%


National HealthCare saw its payout ratio spike in 2022 given the fall in its earnings but is back to more sustainable territory now. The pandemic highlighted a number of risk factors within the skilled healthcare industry that investors previously hadn't focused on. That said, the industry has normally been viewed as a defensive one serving a growing market given America's aging demographics.

In addition, National HealthCare has a pristine balance sheet. It has no long-term debt, while holding a significant cash position. This gives it additional flexibility to navigate the currently choppy waters in its industry.

Final Thoughts & Recommendation

National HealthCare has now fully put its pandemic-related disruptions behind it and has returned to solid growth. Furthermore, the company's strong balance sheet is an asset, and the essential nature of its business leads to steady revenues. But shares have skyrocketed over the past six months, seemingly in large part due to the S&P 600 SmallCap Index adding NHC stock to its holdings late in 2023. While National HealthCare has positive fundamentals, shares have run well beyond our fair value estimate. We forecast 4.1% annual returns and shares earn a hold rating today.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



National HealthCare Corp. (NHC)

Updated March 2nd, 2024, by Ian Bezek

Income Statement Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Revenue	789	872	907	924	964	980	996	981	1,011	1,074
SG&A Exp.	493	550	573	589	612	624	633	650	670	727
D&A Exp.	29	34	37	39	43	42	42	42	41	40
Operating Profit	78	70	70	64	59	61	52	50	60	29
Op. Margin	9.9%	8.1%	7.7%	7.0%	6.1%	6.2%	5.2%	5.1%	5.9%	2.7%
Net Profit	65	53	53	51	56	59	68	42	139	22
Net Margin	8.2%	6.1%	5.9%	5.5%	5.8%	6.0%	6.8%	4.3%	13.7%	2.0%
Free Cash Flow	59	29	25	28	62	69	74	181	23	(21)
Income Tax	38	32	32	30	19	16	20	10	11	7

Balance Sheet Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Total Assets	984	1,074	1,045	1,087	1,097	1,081	1,287	1,362	1,403	1,275
Cash & Equivalents	82	70	38	26	59	43	50	147	108	59
Acc. Receivable	80	79	84	83	87	97	93	90	96	100
Inventories	7	7	8	8	7	7	7	9	9	7
Goodwill & Int.	18	18	18	18	18	21	21	21	175	175
Total Liabilities	296	340	414	418	393	346	508	564	495	398
Accounts Payable	13	16	20	19	16	20	19	21	22	17
Long-Term Debt	10	10	120	120	100	55	10	-	-	-
Total Equity	518	564	631	670	703	733	779	795	903	874
LTD/E Ratio	0.01	0.01	0.19	0.18	0.14	0.08	0.01	-	-	-

Profitability & Per Share Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Return on Assets	6.8%	5.2%	5.0%	4.7%	5.1%	5.4%	5.8%	3.2%	10.0%	1.7%
Return on Equity	12.9%	9.9%	8.9%	7.8%	8.2%	8.2%	9.0%	5.3%	16.3%	2.5%
ROIC	9.5%	7.4%	7.1%	6.6%	7.1%	7.4%	8.6%	5.3%	16.2%	2.5%
Shares Out.	14	14	15	16	15	15	15	15	15	15.5
Revenue/Share	47.25	61.29	62.56	60.73	63.34	64.34	64.87	63.81	65.57	69.55
FCF/Share	3.53	2.01	1.72	1.86	4.08	4.51	4.80	11.80	1.49	(1.39)

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.